One Lever, Many Diseases: The Regenerative Brain Protocol

Over four chapters, the Starved Brain series built one unified picture: cognitive decline as a terrain problem — a brain starved of fuel, blocked from structure, deprived of nutrients, and poisoned by inflammation. If that is true — if these are four faces of one underlying metabolic failure rather than four separate diseases — then something should follow: one correction should help across many different diagnoses. This finale, Part 5 from Dr. Gurpreet Padda at Regen.MD, closes the loop from mechanism to medicine, and states plainly where the evidence is strong and where it is not.

A century-old proof of concept

Before anyone argued about keto on the internet, there was a hospital treatment. For over a hundred years we have known that a ketogenic diet controls seizures. Before effective anti-seizure drugs existed, it was the primary therapy for epilepsy — and it worked. It never went away: today, at the most advanced neurology centers in the world, including Johns Hopkins, ketogenic diet therapy remains a standard of care for drug-resistant epilepsy, with randomized trials showing more than fifty percent seizure reduction in roughly half of patients — in people whom medications had already failed.

Sit with that. A dietary metabolic intervention is first-line, evidence-based neurology for one brain disease, and has been for a century. So the idea that changing the brain’s fuel can change brain disease is not speculative — it is established medicine. The only question is how far it reaches.

Alzheimer’s: feeding the starving brain

Return to where the series started — the Alzheimer’s brain that cannot burn glucose but can still burn ketones. The obvious experiment writes itself: give it ketones. When researchers do exactly that, the brain responds. In a randomized controlled trial, a ketogenic drink improved cognition in people with mild cognitive impairment — the earliest, most reversible stage — over six months. A systematic review and meta-analysis of ten randomized trials, covering 691 patients, concluded that ketogenic interventions improved cognitive function in Alzheimer’s disease. And a randomized crossover trial of a modified ketogenic diet in Alzheimer’s showed improvements in daily function and quality of life.

Here is the truth that is the whole reason to trust this over the hype: these effects are real but modest. The trials are mostly small and short. This is not a cure, and this series will never call it one. What it is — is the first category of intervention in the entire Alzheimer’s field to consistently move cognition in the right direction by addressing the cause, the brain’s energy crisis, rather than chasing a single protein. That is genuinely significant. It is a beginning worth acting on, not a finish line to oversell.

The same lever, other diseases

Now watch the lever move across the map of neurology.

Parkinson’s disease. In a randomized controlled trial, a ketogenic diet improved both motor and non-motor symptoms — and improved the non-motor symptoms (mood, cognition, fatigue) more than a healthy low-fat diet did. And immediately, the honesty this series is built on: the broader review of ketogenic therapy in Parkinson’s is genuinely mixed. A systematic synthesis of the human trials found the evidence scattered and inconsistent, unable to firmly conclude benefit for many outcomes, even while the animal studies looked promising. The signal is real and worth pursuing under supervision; it is not yet settled. Both things are true.

Multiple sclerosis. This is an area of active, exciting clinical work — including case reports of patients improving symptoms and, in some instances, imaging changes — but much of the most dramatic MS work is not yet peer-reviewed. Promising, not proven; treat anyone claiming otherwise with caution.

Huntington’s disease — a devastating genetic disorder — has a published case report of a time-restricted ketogenic diet producing striking motor and functional improvement in one patient. One patient: a signal, not a proof, but a signal in a disease with almost nothing else.

The pattern to see is this: these are not different magic diets for different diseases. This is one correction of the same upstream metabolic failure, applied to different vulnerable circuits — epilepsy, Alzheimer’s, Parkinson’s, and beyond. Supply the brain’s true fuel and building blocks, and remove what starves and inflames it. That is the whole series in one sentence.

But what about my genes?

The objection heard in the office every week: “This runs in my family. Isn’t it just my genes?” There is a gene variant — APOE4 — that is the strongest common genetic risk factor for Alzheimer’s disease. If you carry it, your risk is elevated. That is real. But watch what happens when you change the terrain around those genes.

In a 2026 population study, APOE4 carriers who ate the most meat — the highest quintile, over 800 grams a week — did not show the increased dementia risk their genes would predict; the expected genetic disadvantage, at high meat intake, essentially disappeared in that analysis. And once more, the honesty: this is a single observational study. The strongest statistical signal was in the cognitive-decline measure; the dementia-risk number itself was borderline. It does not prove that meat overrides APOE4. But it fits everything else in this series like a key in a lock, and it points at the most important idea here: your genes may load the gun; your terrain decides whether the trigger is pulled. If dementia runs in your family, that is not a sentence — it is the strongest possible reason to fix your terrain now, while you still have the reserve to regenerate.

The Regen.MD brain protocol

So what does correcting the terrain actually look like — done properly, by a physician, and not off a screen? At Regen.MD, a brain-terrain evaluation is built on the four pillars of this series:

• Fuel. We measure your metabolic and fuel status — glucose, insulin, insulin resistance, ketone capacity — to see whether your brain is in the energy crisis described here, and how to move it toward ketone-based fuel safely, accounting for every medication you take.
• Structure. We review your lipids through the correct lens — sufficiency of the materials the brain is built from — and conduct a careful, physician-to-physician review of any medications, including fat-soluble statins, that may be crossing into the brain. Never a unilateral change.
• Nutrients. We test the canary and the flock — B12 and its functional markers, homocysteine, vitamin D, and the full brain-nutrient panel — against optimal, not merely “normal.”
• Inflammation. We assess the fire — metabolic inflammation, glycation, fatty-acid balance — and treat the mouth as part of the brain’s terrain.

Then we build one personalized correction across all four, because they are one problem. This is regenerative medicine applied to the brain: not a symptom chased, but a terrain repaired, so the organ can recover as far as its reserve allows. And the single most important thing to know: this works best early. The more brain reserve you still have, the more there is to protect and regenerate. Waiting for a diagnosis is waiting too long.

Frequently asked questions

Key takeaways

• Ketogenic therapy is a century-old standard of care for drug-resistant epilepsy — proof that changing the brain’s fuel can change brain disease.
• In Alzheimer’s, ketogenic interventions show real but modest cognitive benefit across randomized trials; other conditions range from mixed to preliminary, and the series states which is which.
• APOE4 raises Alzheimer’s risk but is not destiny; a single 2026 study suggests terrain (high meat intake) may blunt the genetic risk — suggestive, not proof.
• The Regen.MD protocol corrects all four pillars together, under medical supervision, and works best when started early.

Medically reviewed by Gurpreet Singh Padda, MD — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine. Last reviewed July 2026.

This article is educational and is not a substitute for evaluation, diagnosis, or treatment by a physician. Individual results vary; no outcome is guaranteed. Ketogenic and other significant dietary interventions require medical supervision in the presence of chronic disease and can be dangerous without adjustment of medications for diabetes and blood pressure. Do not start, stop, or change any medication or diet without a qualified physician. To build a supervised, personalized plan, apply for a Clinical Evaluation at Regen.MD or call (314) 295-3000 / text (314) 886-5902.

References

1. Wheless JW. History of the ketogenic diet. Epilepsia. 2008;49(Suppl 8):3-5.
2. Haridas B, Testino A, Kossoff EH. Ketogenic diet therapy for the treatment of pediatric epilepsy. Epileptic Disord. 2025;27(2):144-155.
3. Fortier M, Castellano CA, St-Pierre V, et al. A ketogenic drink improves cognition in mild cognitive impairment: results of a 6-month RCT. Alzheimers Dement. 2021;17(3):543-552.
4. Rong L, Peng Y, Shen Q, Chen K, Fang B, Li W. Effects of ketogenic diet on cognitive function of patients with Alzheimer’s disease: a systematic review and meta-analysis. J Nutr Health Aging. 2024;28(8):100306.
5. Phillips MCL, Deprez LM, Mortimer GMN, et al. Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimers Res Ther. 2021;13(1):51.
6. Phillips MCL, Murtagh DKJ, Gilbertson LJ, Asztely FJS, Lynch CDP. Low-fat versus ketogenic diet in Parkinson’s disease: a pilot randomized controlled trial. Mov Disord. 2018;33(8):1306-1314.
7. Grammatikopoulou MG, Tousinas G, Balodimou C, et al. Ketogenic therapy for Parkinson’s disease: a systematic review and synthesis without meta-analysis of animal and human trials. Maturitas. 2022;163:46-61.
8. Phillips MCL, McManus EJ, Brinkhuis M, Romero-Ferrando B. Time-restricted ketogenic diet in Huntington’s disease: a case study. Front Behav Neurosci. 2022;16:931636.
9. Norgren J, Carballo-Casla A, Grande G, et al. Meat consumption and cognitive health by APOE genotype. JAMA Netw Open. 2026;9(3):e266489.